leisure time -WSS

leisure time

author：focus 2025-09-28 02:27:47 - browse：44

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： National associations that represent hospice owe an apology

focus

WSS

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Readout Newsletter: Beam, Prozac, "TechBio" and more

Readout Newsletter: Beam, Prozac, "TechBio" and more

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

How the first Native Hawaiian psychiatrist helped diversify medicine

Intellia plays down concerns on accidental germline transmission

hotspot

leisure time

focus

Duchenne breakthrough therapy leaves behind pioneering families

Wegovy improves function in certain heart failure patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Change Healthcare cyberattack shows risk of industry consolidation

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA advisory panel to debate high blood pressure devices

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Redefining sustainability for the pharmaceutical industry

Medical records are filled with copy

Study: Spinal cord stimulation helps patients with paralysis walk again

entertainment

CDC advisory group OKs chikungunya vaccine

5 ways to address the shortage of health care workers

'Vaccine

Kellogg’s is going to war over Mexico’s nutrition label rules

National associations that represent hospice owe an apology

Virtual repurposing can help discover new uses for existing drugs

Wikipedia

focus

knowledge

Wikipedia